- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02346877
Evaluate Effects of Personalized Patient Counselling for Enbrel® Therapy in Adults With Rheumatoid Arthritis
March 23, 2017 updated by: Amgen
A Multicenter, Historical Control Study to Evaluate the Effects of Personalized Patient Counselling on Persistence to Enbrel® Therapy in Subjects With Rheumatoid Arthritis (PerSuit)
This study will evaluate whether the effect of personalized patient counselling tool, Information-Motivation-Strategy (IMS) based on the results of the Beliefs about Medicines Questionnaire (BMQ) will improve persistence of Enbrel (etanercept) therapy at week 52 in subjects with rheumatoid arthritis over the historical control as estimated by the standard of care.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
19
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Quebec, Canada, G1V 3M7
- Research Site
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3A 1M3
- Research Site
-
-
New Brunswick
-
Fredericton, New Brunswick, Canada, E3B 6H5
- Research Site
-
Quispamsis, New Brunswick, Canada, E2E 4J8
- Research Site
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1C 5B8
- Research Site
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 1Y2
- Research Site
-
Kingston, Ontario, Canada, K7L 2W7
- Research Site
-
Mississauga, Ontario, Canada, L5M 2V8
- Research Site
-
Ottawa, Ontario, Canada, K1S 1C2
- Research Site
-
Peterborough, Ontario, Canada, K9J 2V4
- Research Site
-
-
Quebec
-
Montreal, Quebec, Canada, H2L 1S6
- Research Site
-
Montreal, Quebec, Canada, H3T 1Y3
- Research Site
-
Rimouski, Quebec, Canada, G5L 8W1
- Research Site
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Research Site
-
Trois-Rivieres, Quebec, Canada, G8Z 1Y2
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 100 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject has provided informed consent prior to any study specific procedures
- diagnosed with rheumatoid arthritis and eligible for treatment with Enbrel® (etanercept)
- Subject has been prescribed and has access to commercial Enbrel® (etanercept) (50mg once weekly) according to the subject's health insurance
- Completion of all required safety assessments before starting treatment with Enbrel® (etanercept)
Other Inclusion Criteria May apply.
Exclusion Criteria:
- previously received treatment with a biologic disease modifying antirheumatic drug (DMARD) and/or Tofacitinib.
- Malignancy (except nonmelanoma skin cancers, cervical or breast ductal carcinoma in situ) within the last 5 years
- refusal to consent to enroll in the Enliven program
- Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(s)
Other Exclusion Criteria May Apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Standard of Care Cohort
The first 100 participants will be enrolled in the standard of care (control) cohort.
These participants will receive treatment with Enbrel® (etanercept) in routine clinical practice and will complete a 52 week study period as per the investigator's standard of care.
|
|
Other: Personalized Patient Counselling Cohort
Initiation of the personalized patient counselling cohort will begin after 75% of participants in the control cohort have been analyzed and shown not to have high persistence.
Participants will receive Enbrel® (etanercept) therapy in routine clinical practice and personalized patient counselling based on the Information-Motivation-Strategy (IMS) model based on Beliefs about Medicines Questionnaire (BMQ) baseline results through a patient assistance program for patients on Enbrel (etanercept) therapy.
|
In the interventional cohort participants enrolled on the study will receive personalized patient counselling using the IMS-model based on the baseline BMQ results through a patient assistance program for patients on Enbrel (Etanercept) therapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Persistence of Study Drug Measured at 52 Weeks
Time Frame: 52 weeks
|
A participant is persistent if the date of the last prescription filled plus the number of weeks supply of the prescription is greater than or equal to 52 weeks from enrolment and the eDiary confirms Enbrel® from the prescription was injected.
A participant is not persistent if the last prescription filled plus the number of weeks supply of the prescription is less than 52 weeks from enrolment and the eDiary confirms there was no injection of Enbrel®, or, a participant is not persistent if the participant has a gap in treatment of more than 4 consecutive weeks for no medical reason at any time in the 52 week study period.
|
52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adherence to Study Drug up to 52 Weeks
Time Frame: 52 weeks
|
A participant's adherence is determined as a medication possession ratio (MPR) of at least 80%.
The MPR is the ratio of the total number of weeks' supply, based on pharmacy data, of Enbrel® divided by either 52 weeks or duration on study if a physician stops prescribing Enbrel® due to an adverse drug reaction or lack of efficacy.
|
52 weeks
|
Beliefs About Medicines Questionnaire (BMQ)
Time Frame: 52 weeks
|
BMQ consists of two five-item scales assessing patients' beliefs about the necessity of Enbrel® for controlling their rheumatoid arthritis and their concerns about potential adverse consequences of taking Enbrel®.
Using a five-point Likert scale, on each of necessity and concerns, the individual items within both scales are summed.
The total scores for the Necessity and Concerns Scales range from 5 to 25.
Higher scores indicate stronger beliefs.
|
52 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2015
Primary Completion (Actual)
October 1, 2015
Study Completion (Actual)
October 1, 2015
Study Registration Dates
First Submitted
January 7, 2015
First Submitted That Met QC Criteria
January 21, 2015
First Posted (Estimate)
January 27, 2015
Study Record Updates
Last Update Posted (Actual)
March 27, 2017
Last Update Submitted That Met QC Criteria
March 23, 2017
Last Verified
March 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20130340
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Persistence to Enbrel
-
Shannaz Nadia YusharyahyaUnknownSunscreen PersistenceIndonesia
-
Bispebjerg HospitalUnknownSunscreen Persistence | Vitamin D Production in the SkinDenmark
-
Samsung Medical CenterCompletedAdherence, Medication | Percutaneous Coronary Intervention | Compliance, Medication | Platelet Aggregation Inhibitors | Hydroxymethylglutaryl-coa Reductase Inhibitors | Persistence, MedicationKorea, Republic of
-
Zuyderland Medisch CentrumNederlandse Obesitas KliniekRecruitingObesity, Morbid | Bariatric Surgery Candidate | Medication PersistenceNetherlands
-
University Medical Centre LjubljanaUnknownPersistence of Infection With Helicobacter PyloriSlovenia
-
University of Colorado, DenverCenters for Disease Control and PreventionWithdrawnPersistence of Varicella ImmunityUnited States
-
Cairo UniversityActive, not recruitingTo Try to Eliminate Frequencies of Insertions in Order to Arrive to Adequate Size of Implanted Penile ProsthesisEgypt
-
yongjun wangMinistry of Science and Technology of the People´s Republic of ChinaCompletedIschemic Stroke | Medication PersistenceChina
-
Keele UniversityCompletedPatient Acceptability to Being Invited to Take Part in Research of Relevance to ThemUnited Kingdom
Clinical Trials on Personalized Patient Counselling
-
Chinese University of Hong KongCompleted
-
Singapore General HospitalUnknownDiabetes Mellitus, Type 2 | Neuropathy;PeripheralSingapore
-
The Christie NHS Foundation TrustCompletedCancerUnited Kingdom
-
Guangdong Provincial People's HospitalDongguan People's Hospital; Guangzhou Panyu Central Hospital; First People's... and other collaboratorsUnknown
-
Umeå UniversityVastra Gotaland Region; Region Östergötland; Region Stockholm; Region Örebro County and other collaboratorsActive, not recruitingDiabetes Mellitus, Type 2Sweden
-
University of LuebeckDAK Gesundheit; AOK Schleswig-Holstein; BEK Nord; Draeger and Hanse BKK; IKK Schleswig-Holstein and other collaboratorsCompleted
-
Ottawa Hospital Research InstituteCompletedElective Surgical ProceduresCanada
-
Case Comprehensive Cancer CenterTerminatedAdenocarcinoma of Prostate | Adenocarcinoma of the Prostate Stage I | Adenocarcinoma of the Prostate Stage II | Adenocarcinoma of the Prostate Stage IIIUnited States
-
University Hospital, IoanninaGreece 2021 Committee; Hellenic Stroke Organization; Municipality of North Kynouria and other collaboratorsRecruitingMyocardial Infarction | Heart Diseases | Cardiovascular Diseases | Coronary Disease | Hypertension | Diabetes Mellitus | Dyslipidemias | Peripheral Artery Disease | Cerebrovascular Disease | Stroke (CVA) or TIAGreece
-
Medical Research Council of Southeast SwedenLinkoeping UniversityUnknownCounseling | Education of Patients | Problem-Based LearningSweden